Home / The Importance of Ethnic Diversity in Clinical Trials in NZ
There is evidence that different ethnic groups may respond differently to certain treatments due to genetic and environmental factors. A lack of diversity in clinical trials in NZ can perpetuate health disparities and limit access to treatments for underrepresented groups.
For this reason, pharmaceutical companies around the world desire ethnic diversity in clinical studies to help ensure that treatments are safe and effective for all populations. By including a diverse range of participants, researchers can better understand how treatments affect different groups.
New Zealand’s high cultural diversity with its rich history of indigenous Māori and large population of Pacific Islanders, Asian communities including Chinese, Indian, Korean, and Filipino, as well as other ethnic groups from Europe, Africa, the Middle East, and Latin America makes it an ideal country to run clinical trials.
It is important that clinical studies in NZ are inclusive and representative of the broad population. This is to ensure that the safety and effectiveness of treatments are appropriately assessed for all communities. Having diverse participants complete medical trials in NZ will enable researchers to identify ethnic differences and ensure that treatments are appropriate for all groups.
It’s important to consider the following points when it comes to ethnic diversity in clinical trials.
Overall, while there are potential challenges to achieving ethnic diversity in clinical trials, by increasing diversity in clinical studies in NZ, researchers can gain a better understanding of how treatments work for different populations, reduce health disparities, and improve the effectiveness and safety of treatments for all. By ensuring that medical trials are inclusive, we can improve health outcomes and reduce health inequities.
New Zealand Clinical Research (NZCR) provides state of the art research facilities and the expertise to conduct complex early phase clinical research in healthy participant and patient populations.